Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction
Clinical Trial | By Smits PC, Abdel-Wahab M, Compare-Acute Investigators et al.
BACKGROUND - In patients with ST-segment elevation myocardial infarction (STEMI), the use of percutaneous coronary intervention (PCI) to restore blood flow in an infarct-related coronary artery improves outcomes. The use of PCI in non-infarct-related coronary arteries remains controversial. METHODS - We randomly assigned 885 patients with STEMI and multivessel disease who had undergone primary PCI...
Original Research | By Lønborg J, Engstrøm T, DANAMI 3-PRIMULTI Investigators et al.
BACKGROUND - The impact of disease severity on the outcome after complete revascularization in patients with ST-segment-elevation myocardial infarction and multivessel disease is uncertain. The objective of this post hoc study was to evaluate the impact of number of diseased vessel, lesion location, and severity of the noninfarct-related stenosis on the effect of fractional flow reserve-guided complete revascularization. ...
Clinical Trial | By Engstrøm T, Kelbæk H, DANAMI-3—PRIMULTI Investigators et al.
BACKGROUND - Patients with acute ST-segment elevation myocardial infarction (STEMI) and multivessel coronary disease have a worse prognosis compared with individuals with single-vessel disease. We aimed to study the clinical outcome of patients with STEMI treated with fractional flow reserve (FFR)-guided complete revascularisation versus treatment of the infarct-related artery only. METHODS...
Good response to tolvaptan shortens hospitalization in patients with congestive heart failure
Clinical Trial | By Kogure T, Jujo K, Hamada K et al.
Tolvaptan has been gradually spread to use as a potent diuretic for congestive heart failure in the limited country. However, the response to this aquaretic drug still is unpredictable. A total of 92 patients urgently hospitalized due to congestive heart failure and treated with tolvaptan in addition to standard treatment was retrospectively analyzed. Responder of tolvaptan treatment was defined as a patient with peak negative fluid balance greater th...
Restenosis, Stent Thrombosis, and Bleeding Complications - Navigating Between Scylla and Charybdis
Review Article | By J Torrado, L Buckley, A Durán et al.
The field of interventional cardiology has significantly evolved over 40 years by overcoming several challenges. The introduction of first-generation drug-eluting stents significantly reduced the rates of restenosis, but at the expense of an increase of late stent thrombosis. Prolonged antithrombotic therapy reduced rates of stent thrombosis, but at the cost of increased bleeding. Although the advent of second-generation drug-eluting stents subsequently re...
Review Article | By Bellinger AM, Arteaga CL, Moslehi JJ et al.
Cardio-oncology (the cardiovascular care of cancer patients) has developed as a new translational and clinical field based on the expanding repertoire of mechanism-based cancer therapies. Although these therapies have changed the natural course of many cancers, several may also lead to cardiovascular complications. Many new anticancer drugs approved over the past decade are "targeted" kinase inhibitors that interfere with intracellular signaling contrib...
Clinical Trial | By Catino AB, Hubbard RA, Ky B et al.
BACKGROUND - Sunitinib, used widely in metastatic renal cell carcinoma, can result in hypertension, left ventricular dysfunction, and heart failure. However, the relationships between vascular function and cardiac dysfunction with sunitinib are poorly understood. METHODS AND RESULTS - In a multicenter prospective study of 84 metastatic renal cell carcinoma patients, echocardiography, arterial tonometry, and ...